Health
Health is a sector shaped both by global trends, technologies and innovation, and by local market conditions, demographics and regulations.
Investment and consolidation in Asia are driven by:
- The growth in disposable income, rapidly changing and diversely different demographics;
- Geographically and physiologically distinct characteristics;
- The evolution of government-sponsored health systems; and
- The emergence of true innovators in medical and life science technologies within the region
- Access to these growth markets by global participants, and the thirst of regional actors for M&A in both directions between Asia and the West.
Our global Health team serves our corporate, financial sponsor and entrepreneurial clients by combining our deep local capability and insights across Asia with our global perspectives and transactional track record. Our experience spans healthcare services, medical technology, pharma and biotech, outsourced pharma services (CRO, CDMO), consumer health, and animal & plant life sciences.

Andrew Huntley
Managing Partner, Head of Healthcare

Sanjay Singh
Partner, Head of BDA India, Co-Head Asia Healthcare

Sophia Wu
Senior Advisor

invested in

a portfolio company of

2025

has divested strategic stake to


2025

divested majority stake in

to

2024

acquired majority stake in


2024

has been acquired by


2023

received investment from


2023

a subsidiary of

has acquired

2022

a portfolio company of

has been acquired by

2022

agreed to divest East Syracuse, New York facility to


2022

has sold minority stake to


2022

a portfolio company of

has been acquired by

2022

investment from


2021

has been acquired by


2021

a portfolio company of

has been acquired majority stake by

2021

a portfolio company of

has been acquired by

2021

divested majority stake to


DCP Capital
2021

agreed to divest Couvet, Switzerland facility to WuXi AppTec


2021

raised Series B round from


2021

backed by

has been acquired by

2020

divested Escientia Life Sciences to Deccan Fine Chemicals


2020

divested significant stake in

Kehua Bio-Engineering to Gree Real Estate
2020

majority sale
2019

LAP Lasers a portfolio company of

has been acquired by

2019

divested majority stake to


2019

a portfolio company of

has been acquired by

AGIC and Humanwell
2017

recapitalized majority by


2017

divested CMC Biologics to


2017

has been acquired by a Japanese chemicals & life science company
2016

acquired Adval Tech Medical (Suzhou) and Omni Manufacturing (Mexico)
2013

divested Radiant Research Inc, US-based clinical research company

2012



















